EZH2 and lung carcinoma: Similarly, inhibiting EZH2 has been reported to enhance the sensitivity of the pan‐PI3K inhibitor copanlisib in lung cancer cells harbouring mutated or amplified PIK3CA when the manuscript was in preparation.60